Clear cell sarcoma of the scapula. A case report and review of the literature
© Kazakos et al; licensee BioMed Central Ltd. 2006
Received: 25 April 2006
Accepted: 07 August 2006
Published: 07 August 2006
Clear cell sarcoma of tendons and aponeuroses (CCSTA) appears usually in the extremities and rarely in the trunk.
We present an unusual case of CCSTA overlying the scapular region and with secondary osseous extension in the lower scapula. The patient underwent a wide local excision with removal of the tumor and the lower two thirds of the scapula. He had no local recurrences but he developed lung metastases after 5 months in spite of postoperative chemotherapy. He finally died ten months later.
The patients with CCSTA have a variable unpredictable course. Despite treatment the overall prognosis is poor.
Clear cell sarcoma of tendons and aponeuroses (CCSTA), first described by Enzinger in 1965, is a rare tumor accounting for less than 1% of all soft tissue sarcomas . It has a clear distinction from metastatic melanoma. Patients with CCSTA have a variable unpredictable prognosis. This tumor has a predilection for the lower and upper limbs and rarely presents in the trunk. Sporadic cases only have been reported of CCSTA involving primarily the bone or extending from soft tissues to surrounding bones. We report an unusual case of CCSTA in the left lower scapular region with secondary osseous invasion of the scapula.
A 61-year-old man presented with a painful mass overlying the lower left scapula of four months duration. His pain deteriorated the last three weeks and was accompanied by limitation of the range of motion of the left glenohumeral joint.
Physical examination revealed a subcutaneous tender uniformly firm mass in the lower left scapular region measuring 4.5 × 4.5 cm in diameter. There were no signs of superficial skin inflammation. The patient had not a previous history of melanoma and/or other skin tumors.
After three days a wide excision was carried out and the tumor was removed together with the two thirds of the left scapula and the overlying soft tissues. The remaining bone and soft tissue margins were widely free of tumor. Macroscopic and pathologic examination of the removed mass confirmed the primary diagnosis.
Postoperatively the patient started on a chemotherapy protocol (three courses) consisting of ifosfamide, vincristine and epirubicin. The patient had no local recurrences but he developed lung metastases after 5 months. Despite chemotherapy, he died 10 months later with progressive lung disease.
CCSTA is an aggressive rare soft-tissue tumor with approximately 300 cases totally reported in the English literature . It's a slowly growing tumor often with a long period from the first symptom to diagnosis (averaged 2 years) and seems to have no specific sex predilection. CCSTA can occur in patients of any age. The median age of the patients at the time of diagnosis is 29 years old . In our case the interval between the presentation and the treatment was 4 months suggesting a fast growing tumor.
Commonly the presenting symptom is a painless mass or swelling. Pain and/or tenderness above the tumor site may be found in 33–50% of all the patients suffered from CCSTA. Typically CCSTA has the appearance of a palpable deep-located soft tissue mass bound to an adjacent tendon or aponeurosis. The overlying skin may occasionally appear with discoloration [4, 5]. Intralesional calcifications are rarely seen and primary [2, 6, 7] or secondary [8, 9] bone invasion by this tumor is very rare.
Frequently it arises in the extremities with a predilection for the lower limbs (78–97%). Both foot and ankle are the commonest sites of tumor appearance accounting 33–65% of all cases. Next most common sites are the knee, thigh, hand, forearm, elbow and shoulder in descending order of frequency; rarely the tumor arises in the head, neck or trunk [5, 10, 11].
Primary CCSTA overlying the scapular region, as in our case, is very uncommon with only a few case reports have been described [5, 12]. This tumor has an unclear histological origin; there are many theories concerning histogenesis of CCSTA such as synovial origin, neural crest derivation or being an atypical malignant melanoma [5, 12]. Tsuneyoshi et al  subdivided CCSTA into synovial and melanotic types based of melanin presence and histological and cytological differences.
Usually CCSTA has the appearance of a lobular or multinodular, circumscribed or encapsulated mass with a gray-white appearance on cut surface. Hemorrhage and necrosis may be present in large tumors. Intralesional calcifications are rarely seen . Histologically, CCSTA is composed of round and/or fusiform cells arranged in nests separated by fibrocollagenous tissue. These cells have a relatively uniform appearance of round to ovoid vesicular nuclei with prominent nucleoli and with clear (in two-thirds of tumors perhaps due to intracytoplasmic glycogen) or eosinophilic cytoplasm. A small number of giant cells with more than 12–15 nuclei may be seen  but there were not wreath-like giant cells in our case. Fibrous tissue septa are often contiguous with the fibers of the involved tendons and aponeuroses.
Immunohistochemically, the tumor cells are usually positive for S-100 protein, HMB-45 and vimentin and/or microphthalmia transcription factor . Cytokeratins (low molecular weight) may be found in the tumor cells . Usually intracellular melanin is scanty although many reported series refer that about 50–75% of CCSTA contain variable amounts of melanin which can be identified by melanin stains [4, 5, 11, 12]. Ultrastructurally melanosomes may be present . In our case the tumor did not contain melanin.
CCSTA is associated with chromosomal abnormalities consisting of changes in chromosome number and chromosome rearrangements [9, 14, 16]. Cytogenetic analysis of CCSTA identifies abnormalities in most chromosomes. A t(12;22)(q13;q12) translocation may be found in 75% of cases with CCSTA by karyotype analysis. Many authors suggest that this translocation seems to be pathognomonic for CCSTA [9, 17].
Distinction between CCSTA and metastatic malignant melanoma may have diagnostic difficulties. Both tumors have similar histological features. However tumor presentation (especially location, cutaneous involvement, primary melanoma elsewhere) and histological features help to make a differential diagnosis between these tumors . Both CCSTA and malignant melanoma are immunohistochemically positive for S-100 protein (a marker for tumors derived from neural crest) and HMB-45 (a marker identifying tumors associated with melanoma)  suggesting that these tumors have a close relationship. Primary and metastatic melanoma usually has a different genetic profile. The t(12;22)(q13;12) translocation has not yet been identified in melanoma [9, 14]. Recent reports refer that there is a high incidence of activating mutations in the kinase domain of the BRAF gene in malignant melanoma of the skin while in CCSTA the BRAF mutations are rare [19, 20].
The treatment of choice for patients with CCSTA is wide excision of the tumor or amputation with excision of regional lymph nodes. Adjuvant radiotherapy and/or aggressive multiagent chemotherapy seem to be ineffective but probably could be given [3–5, 21, 22]. Surgical excision, adjuvant radio- or chemotherapy or a combination of these three treatments seems to have no advantage of one therapy over another [4, 21]. Our patient was submitted to surgical excision and chemotherapy and yet died after only ten months.
The patients with CCSTA have a variable unpredictable course. Despite treatment the overall prognosis is poor and subsequent wide spread dissemination of disease lead patients with CCSTA to death. The 5-year survival rate with radical excision and adjuvant chemotherapy and/or radiotherapy ranged from 60 to 67% and the 10-year survival rate is about 33% [4, 5, 10, 11]. The incidence of local recurrence after primary surgical treatment is very high. Enzinger  reports incidence of 84% of first local recurrence (with 1–10 subsequent local recurrences), while in the series reported by Pavlidis  5 of six cases developed local recurrence in 3 to 9 months.
Usually there is a median interval time between the primary treatment and first local recurrence ranged from 6 months to 1 year [11, 12]. Therefore primary wide surgical excision of the tumor is warranted to decrease local recurrences. In our case no local recurrence was present after ten months.
The most common sites of metastases are the regional lymph nodes and the lungs and less common skin, bones, liver, heart and brain [2, 5, 11]. 60–70% of patients with CCSTA develop metastases at a mean time interval of 18 months to 6 years [1, 5]. Perhaps preoperative duration of symptoms, tumor size, mitotic index or vascular invasion may not predict survival in these patients . Some authors believe that the size of tumor defines a better or worse survival. Tumors greater than 5 cm have a worse survival and they warrant more aggressive local surgical treatment being at high risk of distant metastases [3, 21] while in Deenik series  patients with tumor size less than 2 cm had a better survival.
Written consent of the patient could not be obtained and hence ethical committee permission was obtained for publication of his case report.
- Enzinger FM: Clear-cell sarcoma of tendons and aponeuroses: an analysis of 21 cases. Cancer. 1965, 18: 1163-1174. 10.1002/1097-0142(196509)18:9<1163::AID-CNCR2820180916>3.0.CO;2-0.View ArticlePubMed
- Gelczer RK, Wenger DE, Wold LE: Primary clear cell sarcoma of bone: a unique site of origin. Skeletal Radiol. 1999, 28: 240-243. 10.1007/s002560050509.View ArticlePubMed
- Finley JW, Hanypsiak B, Mcgrath B, Kraybill W, Gibbs JF: Clear cell sarcoma: The Roswell Park experience. Journal of Surgical Oncology. 2001, 77: 16-20. 10.1002/jso.1057.View ArticlePubMed
- Lucas DR, Nascimento AG, Sim FH: Clear cell sarcoma of soft tissues: Mayo Clinic experience with 35 cases. Am J Surg Pathol. 1992, 16: 1197-1204.View ArticlePubMed
- Pavlidis NA, Fisher C, Wiltshaw E: Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer. 1984, 54: 1412-1417. 10.1002/1097-0142(19841001)54:7<1412::AID-CNCR2820540730>3.0.CO;2-A.View ArticlePubMed
- Brekke MK, Northcote K, Temple WE: Clear cell sarcoma in the first metatarsal. An unusual case. J Am Podiatr Med Assoc. 1998, 88: 457-61.View ArticlePubMed
- Yokoyama R, Mukai K, Hirota T, Beppu Y, Fukuma H: Primary malignant melanoma (clear cell sarcoma) of bone. Report of a case arising in the ulna. Cancer. 1996, 77: 2471-2475. 10.1002/(SICI)1097-0142(19960615)77:12<2471::AID-CNCR9>3.0.CO;2-P.View ArticlePubMed
- Morishita S, Onomura T, Yamamoto S, Nakashima Y: Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) with unusual roentgenologic findings. Clin Orthop. 1987, 216: 276-279.PubMed
- Nedoszytko B, Mrozek K, Roszkiewicz A, Kopacz A, Swierblewski M, Limon J: Clear cell sarcoma of tendons and aponeuroses with t(12;22) (q13;q12) diagnosed initially as malignant melanoma. Cancer Genet Cytogenet. 1996, 91: 37-39. 10.1016/S0165-4608(96)00113-6.View ArticlePubMed
- Marques B, Terrier P, Voigt JJ, Mihura J, Coindre JM: Clear cell soft tissue sarcoma. Clinical, histopathological and prognostic study of 36 cases. Ann Pathol. 2000, 20: 298-303.PubMed
- Enzinger FM, Weiss SW: Soft Tissue Tumors. 1995, St Louis, Mosby-Year Book Inc, 913-919. 3
- Tsuneyoshi M, Enjoji M, Kubo T: Clear cell sarcoma of tendons and aponeuroses. A comparative study of 13 cases with a provisional subgrouping into the melanotic and synovial types. Cancer. 1978, 42: 243-252. 10.1002/1097-0142(197807)42:1<243::AID-CNCR2820420138>3.0.CO;2-N.View ArticlePubMed
- Hazra S, Weiner SD, Senior ME, Seth A: Painless enlarging subcutaneous mass in a 58-year-old woman. Clin Orthop. 2000, 370: 311-319. 10.1097/00003086-200001000-00031.View ArticlePubMed
- Graadt van Roggen JF, Mooi WJ, Hogendoorn PC: Clear cell sarcoma of tendon and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. J Pathol. 1998, 186: 3-7. 10.1002/(SICI)1096-9896(199809)186:1<3::AID-PATH153>3.0.CO;2-V.View ArticlePubMed
- Mooi WJ, Deenik W, Peterse JL, Hogendoorn PC: Keratinimmunoreactivity in melanoma of soft parts (clear cell sarcoma). Histopathology. 1995, 27: 61-65.View ArticlePubMed
- Speleman F, Delattre O, Peter M, Hauban E, van Roy N, van Marck E: Malignant melanoma of the soft parts (clear cell sarcoma): confirmation of EWS and ATF-1 gene fusion caused by a t(12;22) translocation. Mod Pathol. 1997, 10: 496-499.PubMed
- Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: clear cell sarcoma (malignant melanoma of soft parts). Cancer Genet Cytogenet. 2001, 130: 1-7. 10.1016/S0165-4608(01)00462-9.View ArticlePubMed
- Chung EB: Clear cell sarcoma: a tumor of probable neuroectodermal origin. Contemp Issues Surg Pathol. 1991, 18: 259-263.
- Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003, 9: 6483-6488.PubMed
- Panagopoulos I, Mertens F, Isaksson M, Mandahl N: Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet Cytogenet. 2005, 156: 74-76. 10.1016/j.cancergencyto.2004.04.008.View ArticlePubMed
- Sara AS, Evans HL, Benjamin RS: Malignant melanoma of soft parts (clear cell sarcoma): A study of 17 cases with emphasis on prognostic factors. Cancer. 1990, 65: 367-374. 10.1002/1097-0142(19900115)65:2<367::AID-CNCR2820650232>3.0.CO;2-X.View ArticlePubMed
- Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB: Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer. 1999, 86: 969-975. 10.1002/(SICI)1097-0142(19990915)86:6<969::AID-CNCR11>3.0.CO;2-Z.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.